News for SBBP Stock

Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc. Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases Strongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update Strongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021 Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO) Strongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare Conference Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021 Strongbridge Biopharma plc Announces Promotion of Richard S. Kollender to President and Chief Financial Officer Strongbridge Biopharma plc Announces New Employment Inducement Awards Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary Strongbridge Biopharma plc Announces Participation in Two Upcoming Investor Conferences Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate Update Strongbridge Biopharma plc to Host Third Quarter 2020 Financial Results Conference Call on October 29, 2020 Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares Strongbridge Biopharma plc Provides Corporate Update Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome Strongbridge Biopharma plc to Present at the Jefferies Virtual Healthcare Conference Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series Strongbridge Biopharma plc Reports First Quarter 2020 Financial Results and Provides Corporate Update Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020